Search clinical trials for: BIA 5-453

Total 16465 results

Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]- Labeled BIA 5-453 and Metabolites

Hypertension | Congestive Heart Failure

Switzerland
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 5-453 and Its Metabolites

Hypertension | Chronic Heart Failure

France
Bial - Portela C S.A.

Completed

Bioavailability Study of BIA 5-453

Hypertension | Congestive Heart Failure

France
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453

Hypertension | Chronic Heart Failure
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of BIA 5-453

Hypertension

France
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Dopamine ß-hydroxylase (DßH) Inhibition Profile of BIA 5-453

Hypertension | Chronic Heart Failure

France
Chang Gung Memorial Hospital

Completed

Application of Serial Body Composition Change for Risk Prediction in Treating Patients With Severe Pneumonia

Pneumonia

Taiwan
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C] Labelled BIA 5-1058

Cardiovascular Diseases

United Kingdom
Universitair Ziekenhuis Brussel
Baxter Healthcare Corporation

Recruiting

Intra Dialytic Parenteral Nutrition and Nutritional Gap Nutritional Gap Identified by Indirect Calorimetry (DiaPaNIC)

Chronic Kidney Diseases | Protein Energy Wasting

Belgium
Suzhou Kintor Pharmaceutical Inc,
Suzhou Koshine Biomedica, Inc.

Active, not recruiting

Phase III Study of KX-826 With Adult Male Patients With AGA

Androgenetic Alopecia

China
University of Copenhagen
Zealand University Hospital

Completed

The Relationship Between Fat Free Mass and Toxicity of Cytostatics in Cancer Patients

Colorectal Cancer | Pancreas Cancer

Denmark
University Hospital, Ghent

Completed

Watershift - Pilot Study (WATERSHIFT)

Nocturnal Polyuria | Total Body Water

Belgium
Pfizer

Terminated

An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia

Schizophrenia

United States
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Ruxolitinib as GVHD Prophylaxis in AA Patients

The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA
Bial - Portela C S.A.

Completed

Effect of Food on BIA 5-1058

Pulmonary Arterial Hypertension
Suzhou Kintor Pharmaceutical Inc,

Completed

Phase II Study Evaluating the Efficacy and Safety of KX-826

Androgenetic Alopecia (AGA)

China
Bial - Portela C S.A.

Terminated

Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058

Pulmonary Arterial Hypertension
Bial - Portela C S.A.

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058

Pulmonary Arterial Hypertension | Cardiovascular Disease+Pulmonary Disease

United Kingdom
Miulli General Hospital

Unknown

Probing the Dry Weight by Bioimpedance: The Resistance Stabilization Test

Uremia

Italy
Bial - Portela C S.A.

Completed

Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH

Pulmonary Arterial Hypertension

Spain
Bial - Portela C S.A.

Completed

Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058.

Hypertension and Chronic Heart Failure

Netherlands
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of BIA 5-1058 (ADME)

Pulmonary Arterial Hypertension

Netherlands
BDH-Klinik Hessisch Oldendorf

Recruiting

Influence of the Body Composition of Neurological (Early) Rehabilitants on Rehabilitation Success

Neurological Rehabilitation

Germany
Klinikum St. Georg gGmbH

Completed

Malnutrition Using GLIM Criteria and Comparing CT and BIA for Muscle Mass Measurement

Malnutrition
University Ghent

Completed

Food and Salt Handling in Diuresis

Nocturia | Polyuria

Belgium
Bial - Portela C S.A.

Completed

Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics

Pulmonary Arterial Hypertension

Germany
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

First in Human Study of M4344 in Participants With Advanced Solid Tumors

Solid Tumor | Advanced Solid Tumor

Spain, United States, Netherlands, United Kingdom
Bial - Portela C S.A.

Completed

Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine

Partial Epilepsy

Belgium
Mahidol University

Completed

BIA-Guided Dry Weight Assessment on Sleep Quality in Chronic Hemodialysis Patients (BEDTIME)

Renal Failure Chronic Requiring Hemodialysis | Poor Quality Sleep

Thailand
The Lymphoma Academic Research Organisation

Recruiting

Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry

Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL)

Belgium, France
Hamamatsu University

Completed

Comparison of Vonoprazan-based Dual and Triple Therapies for H. Pylori Eradication

Gastritis Associated With Helicobacter Pylori

Japan
Merck Sharp & Dohme LLC

Completed

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension

Chronic Cough

China
University of Michigan
Department of Health and Human Services

Completed

ABC Brain Games Self-Regulation Intervention

Obesity | Self-Regulation

United States
Maternal Fetal Medicine Associates

Unknown

Bioelectric Impedance Analysis and Pregnancy Outcomes

Pregnancy Complications

United States
Bial - Portela C S.A.

Completed

Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil

Pulmonary Arterial Hypertension

Germany
Bial R&D Investments, S.A.

Recruiting

Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD (ACTIVATE)

Parkinson's Disease

United States, Spain, France, Italy, Netherlands, Germany, United Kingdom, Canada, Poland, Portugal, Sweden
Pennington Biomedical Research Center

Completed

Samsung Galaxy Watch Body Composition Study

Obesity | Overweight

United States
Jens Rikardt Andersen
Hillerod Hospital, Denmark

Completed

Body Composition Measurements in Pneumonia

Acute Infection Respiratory

Denmark
Bial - Portela C S.A.

Completed

Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil

Pulmonary Arterial Hypertension

Germany
Galderma R&D

Completed

Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma

Basal Cell Carcinoma

United States
Samuel Lunenfeld Research Institute, Mount Sinai...

Active, not recruiting

Association of Body Fluid Distribution With Obstructive Sleep Apnea in Pregnant Women With Body Mass Index ≥ 40 kg/m2

Obesity | Apnea, Obstructive Sleep

Canada
Merck Sharp & Dohme LLC

Completed

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)

Chronic Cough

Canada, Czechia, Denmark, Hungary, Peru, Poland, Ukraine, United Kingdom, United States, Australia, China, Colombia, Germany, Guatemala, Israel, Italy, Malaysia, New Zealand, South Africa, Turkey
University Health Network, Toronto
Society of Anesthesia and Sleep Medicine

Completed

Postoperative Rostral Fluid Shift and Obstructive Sleep Apnea

Obstructive Sleep Apnea

Canada
Bial - Portela C S.A.

Completed

Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Bosentan

Pulmonary Arterial Hypertension

Germany
Ohio University

Recruiting

Comparison Of Measured To Predicted Resting Metabolism

Body Weight

United States
Thammasat University Hospital

Completed

Optimal Frequency of Total Body Water Measurements by Bioelectrical Impedance Analysis to Prevent Intradialytic Hypotension

End Stage Renal Disease on Dialysis | Intradialytic Hypotension

Thailand
Amsterdam UMC, location VUmc

Completed

Relation Between Bioelectrical Impedance Analysis (BIA) and CT-scan Analysis in the ICU (ICUBIACT)

Muscular Atrophy
Bial - Portela C S.A.

Completed

Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202

Parkinson's Disease

United Kingdom
Bial R&D Investments, S.A.

Completed

Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156

Parkinson Disease

United Kingdom
Bial - Portela C S.A.

Completed

Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202

Parkinson's Disease

United Kingdom

Search clinical trials for: BIA 5-453

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations